Blood Journals Portfolio/LinkedIn
Sep 9, 2025, 23:00
Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
Blood Journals Portfolio shared on LinkedIn:
”September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD!
In this episode, “Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor” the methodology of three articles are discussed that feature sickle cell disease studies.
Key points are:
- Ruxolitinib plus Dexamethasone in Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis (HLH): A prospective study demonstrated that the combination of ruxolitinib and dexamethasone (Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult HLH patients. All patients responded to the treatment, and no significant adverse effects were observed.
- Lysine-Specific Demethylase-1 (LSD1) Inhibitors in Sickle Cell Disease: Novel, potent, and orally bioavailable LSD1 inhibitors have been shown to induce fetal hemoglobin synthesis in a sickle cell disease mouse model. These inhibitors effectively reduce reactive oxygen species and improve red blood cell lifespan, offering a promising new class of therapies for sickle cell disease and other beta-globinopathies.
- Clinical Characteristics of Patients with Low Von Willebrand Factor: Insights into the clinical phenotype and pathophysiological mechanisms underlying qualitative low von Willebrand factor (VWF) have been explored. Patients with plasma VWF levels between 30 to 50 IU/dL often present with mucocutaneous bleeding and may require tailored management strategies.
Listen to the full episode here.
What are your thoughts on these advancements in sickle cell disease research?”
Stay tuned for the podcast series in hematology with Hemostasis Today.
-
Oct 25, 2025, 10:13Meet the 2025 WSO Award Winners for Their Extensive Contributions to Stroke Science
-
Oct 25, 2025, 09:53Aakanksha A Shares The 1st Post in ASH 12-Part Microlearning Series
-
Oct 25, 2025, 09:22Alessandro Bufi Presented SAIDE Project at World Stroke Congress 2025
-
Oct 25, 2025, 09:06A Short Story About a Platelet Named Pippa from Krista Goerger
-
Oct 25, 2025, 08:31Maxime Dely: What if We Could Leukoreduce Without a Filter?
-
Oct 24, 2025, 12:08Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
-
Oct 24, 2025, 12:03Melissa Glasner on Integration of Gene Therapy Into Hemophilia Care
-
Oct 24, 2025, 11:41Yaping Zhang on Platelet Adhesion Receptors
-
Oct 24, 2025, 11:37Omid Jafari and Colleagues Present the VTE-BERT Natural Language Processing Model
-
Oct 24, 2025, 11:34Insights on IV Thrombolysis and Mechanical Thrombectomy from Benjamin Maier and Colleagues
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 25, 2025, 09:32Sylaja Pn Wins 2025 WSO Presidential Award
-
Oct 25, 2025, 08:21Courtney Lawrence: Listen. Empower. Deliver. Save Lives!
-
Oct 25, 2025, 08:14Hema Tallman on Incredible Opportunity to Participate in the PPTA 2025 Meetings
-
Oct 24, 2025, 11:28Louise Bannon and Thomas Reiser Thank World Thrombosis Day Supporters Around The World
-
Oct 24, 2025, 10:48Melanie Daniel Congratulates Mickael Rosa and Antoine Rauch on Winning Bernd R. Binder Prize
Oct 25, 2025, 09:53
Oct 25, 2025, 09:32
Oct 25, 2025, 09:22
Oct 25, 2025, 09:06
Oct 25, 2025, 08:31
Oct 25, 2025, 08:21
Oct 25, 2025, 07:41
Oct 24, 2025, 12:03